Roche Hldg Ltd Spons: (OTC: RHHBY)
$61.90
-0.55 (-0.88%)
Volume 134,169
Jun 19 03:56 PM ET
Zacks Rank: 4-Sell 
| #4 |
Overview Quote
Stock Activity
| Day Low - High | 61.72 - 62.85 |
| 52wk Low - High | 41.38 - 66.52 |
| Previous Close | 62.45 |
| Avg. Volume | 542,291 |
| Industry | LARGE CAP PHARMA |
| Market Cap | 215.47 B |
| Div - Yield | 1.62 - 2.60 |
| Beta | 0.66 |
| P/E (F1) | 15.92 |
| Current Year Est. | 3.92 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
 4 |
Zacks Recommendation
|
No Zacks Recommendation |
Zacks Industry Rank
|
175 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| P/E (F1) | 15.92 |
| PEG Ratio | 2.01 |
| Current Year Est. | 3.92 |
| Current Quarter Estimate | NA |
| Most Accurate Estimate | NA |
| Earnings ESP |
NA |
| Next Earnings Report Date | NA |
| EPS Last Year | NA |
| Expected Earnings Growth | 7.92% |
Company Description
Roche Holding AG is a research-based, product-focused organization dedicated to the discovery and early clinical development of pharmaceuticals and drugs, fine chemicals and vitamins, fragrances and flavors, diagnostic equipment and liquid crystals. The Company distributes its products throughout Europe, the United States, Asia and Latin America.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (03/2013) |
Next Qtr (06/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | NA | NA | 3.92 | 4.22 |
| Number of Estimates | 0 | 0 | 3 | 3 |
| Low Estimate | NA | NA | 3.82 | 4.11 |
| High Estimate | NA | NA | 4.04 | NA |
| Year Ago EPS | NA | NA | 3.69 | 3.92 |
| EPS Growth | NA | NA | 6.32% | 7.56% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| ROCHE HLDG LTD | RHHBY | 62.45 | |
|
| NOVO-NORDISK AS | NVO | 161.87 | |
|
| ABBOTT LABS | ABT | 37.51 | |
|
| ABBVIE INC | ABBV | 43.54 | |
|
| ALLERGAN INC | AGN | 101.49 | |
|
| ASTRAZENECA PLC | AZN | 50.98 | |
|
| BRISTOL-MYERS | BMY | 46.85 | |
|
| GLAXOSMITHKLINE | GSK | 52.47 | |
|
| JOHNSON & JOHNS | JNJ | 86.36 | |
|
| LILLY ELI & CO | LLY | 52.35 | |
|
Sector:Medical>> Industry:LARGE CAP PHARMA
COMPARE TICKER vs. Its Peers
Zacks Commentary
Gilead Presents Idelalisib Data
Jun 19, 2013
PDL BioPharma Guides Higher 2Q Royalties
Jun 13, 2013
Label Expansion for Roche's RoActemra
Jun 12, 2013
Orphan Drug Status for ViroPharma's Maribavir
Jun 12, 2013
Glaxo Reports Disappointing Tykerb Data
Jun 10, 2013
Encouraging Data on Novartis Candidate
Jun 10, 2013
Pipeline Progress at Roche
Jun 10, 2013
Positive Data on Novartis' Afinitor
Jun 07, 2013
Financials
| EPS TTM | NA |
| Sales | 49,208 |
| Net Income | NA |
| Price/Earnings | NA |
| Price/Book | 12.07 |
| Price/Cash Flow | 14.20 |
| Price/Sales | NA |
News
Lab Automation Market Report - Trends & Global Forecasts to 2017 - M2
Jun 17, 2013
Amgen Drug Delays Ovarian Cancer Re-Growth, Survival Benefit Unclear - TheStreet.com
Jun 12, 2013
Can This Experimental Drug Be Brought Back From the Dead? - TheMotleyFool
Jun 12, 2013
Seattle Genetics announces encouraging data from cancer trials - Datamonitor
Jun 12, 2013
Winners And Losers in CLL at ASCO `13 - TheStreet.com
Jun 10, 2013
Is This GlaxoSmithKline`s Next Big Blockbuster? - TheMotleyFool
Jun 7, 2013
This Pharma Is Trading Like a Biotech - TheMotleyFool
Jun 4, 2013
Uncovering cancer in today's anatomic pathology lab - Pr Newswire
Jun 4, 2013
Broker Recommendations
| Current ABR | 1.00 |
| ABR (Last Week) | 1.00 |
| # of recs in ABR | 4 |
| Average Target Price | 60.01 |
| Industry Rank by ABR | 175 out of 265 |
| Rank in Industry | 14 out of 15 |
